Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cuprina Holdings (Cayman)CUPR -3.49%10 3-Year EBITDA Growth Rate is -66.70% as of Dec. 2025. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 694 Medical Devices & Instruments companies, Cuprina Holdings (Cayman) ranks worse than 98.27% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -66.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cuprina Holdings (Cayman) was -41.60% per year. The lowest was -66.70% per year. And the median was -54.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cuprina Holdings (Cayman) 3-Year EBITDA Growth Rate Related Terms
CUPR vs BNGO, UEEC, FEMY: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Cuprina Holdings (Cayman)'s 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuprina Holdings (Cayman) 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cuprina Holdings (Cayman)'s 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cuprina Holdings (Cayman)'s 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -66.70% mean?
Cuprina Holdings (Cayman) (CUPR) has a 3-Year EBITDA Growth Rate of -66.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cuprina Holdings (Cayman) and its competitors. According to the industry distribution chart, Cuprina Holdings (Cayman) ranks #682 out of 694 companies in the Medical Devices & Instruments industry, placing it in the top 98.3%.
Is Cuprina Holdings (Cayman)'s 3-Year EBITDA Growth Rate too high?
Cuprina Holdings (Cayman)'s current 3-Year EBITDA Growth Rate is -66.70%. Based on the distribution chart, Cuprina Holdings (Cayman) ranks #682 out of 694 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s 3-Year EBITDA Growth Rate compare to BNGO and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Cuprina Holdings (Cayman) ranks #682 out of 694 companies for 3-Year EBITDA Growth Rate. This places Cuprina Holdings (Cayman) in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.55, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cuprina Holdings (Cayman) and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuprina Holdings (Cayman)'s current 3-Year EBITDA Growth Rate is -66.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current 3-Year EBITDA Growth Rate of -66.70%. The current 3-Year EBITDA Growth Rate is -66.70%. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current 3-Year EBITDA Growth Rate is -66.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
